The estimated Net Worth of Brian Jg Pereira is at least 12 百万$ dollars as of 3 August 2009. Brian Pereira owns over 5,000 units of KalVista Pharmaceuticals Inc stock worth over 353,503$ and over the last 18 years he sold KALV stock worth over 11,581,968$. In addition, he makes 47,500$ as Independent Director at KalVista Pharmaceuticals Inc.
Brian has made over 11 trades of the KalVista Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 230,011 units of KALV stock worth 10,065,281$ on 9 November 2009.
The largest trade he's ever made was selling 230,011 units of KalVista Pharmaceuticals Inc stock on 9 November 2009 worth over 10,065,281$. On average, Brian trades about 14,497 units every 36 days since 2006. As of 3 August 2009 he still owns at least 32,976 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Brian Pereira stock trades at the bottom of the page.
Dr. Brian J. G. Pereira M.D. serves as Independent Director of the Company. Dr. Pereira has served as a member of our Board since February 2019. Dr. Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. He has been President & CEO of Visterra, Inc. since 2013 and continues to serve in this role after the acquisition by Otsuka in August 2018. He previously served as President & CEO of AMAG Pharmaceuticals where he raised four financing rounds at increasing valuations and built the clinical development, manufacturing, supply-chain and commercial infrastructure for Feraheme. Prior to AMAG Pharmaceuticals, he held senior roles at Tufts Medical Center, including President and CEO of a Tufts Medical Center Physician Organization and interim COO. Brian is Executive Chairman of the Board of Directors of Abeona Inc., and Chairman of the Board of Directors of Africa Healthcare Network. He serves on the Board of Cullinan Pearl Corp and Visterra, Inc, and has previously served on the Board of several private and public companies. He serves on the Board of Directors of the America India Foundation and Board of Advisors of Life Sciences Cares. He was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles. He received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute and MBA from Kellogg School of Management at Northwestern University. Pereira is qualified to serve on our Board because of his extensive experience in and knowledge of our industry.
As the Independent Director of KalVista Pharmaceuticals Inc, the total compensation of Brian Pereira at KalVista Pharmaceuticals Inc is 47,500$. There are 11 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of 1,731,160$.
Brian Pereira is 61, he's been the Independent Director of KalVista Pharmaceuticals Inc since 2019. There are 4 older and 12 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over 74,823,944$ worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth 58,591,487$ . The most active insiders traders include Holdings A/S Novo、Capital Management, L.P.Ra ...、Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of 835,088$. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth 167,500$.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: